NCT07712757尚未招募3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Safusidenib in Participants With Grade 2 Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 140
- 主要终点
- Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0
研究概览
简要总结
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study comparing the efficacy and safety of safusidenib versus placebo in participants with residual or recurrent Grade 2 glioma (oligodendroglioma or astrocytoma) with an IDH1 mutation who have undergone surgery as their only treatment and are not in need of immediate chemotherapy or radiotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
The Sponsor and Sponsor representatives (including the CRO) will be blinded to the treatment assignment.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Expected survival of ≥12 months.
- •At least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection), with the most recent surgery having occurred at least 90 days (or at least 28 days if biopsy only and postoperative changes have resolved per BICR) and no longer than 5 years before the date of randomization
- •Have not had any other prior anticancer therapy, including chemotherapy and radiotherapy; and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator.
- •Histologically confirmed Grade 2, IDH1-mutant oligodendroglioma or astrocytoma according to World Health Organization Central Nervous System 2021 classification criteria per Investigator assessment.
- •IDH1 mutation (R132H/C/G/S/L), identified by polymerase chain reaction, next-generation sequencing (NGS), or immunohistochemistry; and confirmed 1p19q codeletion status by fluorescence in situ hybridization, NGS, or array comparative genomic hybridization.
- •Residual or recurrent, measurable, non-enhancing disease, as confirmed by BICR per RANO 2.0, assessed at Screening.
- •Adequate hematologic and organ functions
排除标准
- •Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) for treatment of glioma, including chemotherapy, investigational therapies, prior therapies targeting IDH1 or IDH2, anti-angiogenic therapies, tumor-treating fields, or radiotherapy.
- •High-risk features as assessed by the Investigator, including brainstem or spinal cord involvement either as primary location or by significant tumor extension, clinically relevant functional or neurocognitive deficits due to the tumor (deficits resulting from surgery are allowed), or uncontrolled seizures (defined as persistent seizures interfering with ability to comply with protocol requirements).
- •Evidence of leptomeningeal disease.
- •Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of <1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.
结局指标
主要结局
Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0
时间窗: From the date of randomization until the date of first documented disease progression, approximately 30 months
PFS, defined as time from date of randomization to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR or death from any cause, whichever occurs earlier
次要结局
- Objective Response Rate (ORR) assessed by BICR per modified RANO 2.0(From the date of randomization until the date of first documented disease progression, approximately 30 months)
- Time to Next Intervention (TTNI)(From the date of randomization until the date of the start of another anticancer treatment or date of death, approximately 30 months)
- PFS assessed by the Investigator per modified RANO 2.0(From the date of randomization until the date of first documented disease progression, approximately 30 months)
- ORR assessed by the Investigator per modified RANO 2.0(From the date of randomization until the date of the first documented disease progression, approximately 30 months)
- Duration of Response (DOR) assessed by BICR and by the Investigator per modified RANO 2.0(From the date of randomization until the date of first documented disease progression, approximately 30 months)
- Time to Response (TTR) assessed by BICR and by the Investigator per modified RANO 2.0(From randomization to the first documentation of objective response (CR, PR, or MR), approximately 30 months)
- Disease Control Rate (DCR) assessed by BICR and by the Investigator per modified RANO 2.0(From the date of randomization until the date of first documented disease progression, approximately 30 months)
- Tumor Growth Rate (TGR) by volume assessed by BICR(From historical scans through the final scan in the study, approximately 30 months)
- Overall Survival (OS)(From the date of randomization until the date of death, approximately 30 months)
- Safety and tolerability(From the first dose of study drug until 30 days after treatment discontinuation, approximately 30 months)
- Safusidenib PK Profile(From the first dose of study drug through approximately 16 weeks)
- Health-Related Quality of Life(From the first dose of study drug to treatment discontinuation, approximately 30 months)
- Seizure Activity(From the date of randomization until the date of first documented disease progression, approximately 30 months)
研究者
相似试验
尚未招募
3 期
PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) StudyType 1 Diabetes (T1D)NCT07670650University of Florida108
招募中
3 期
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyNCT07266805Pharvaris Netherlands B.V.32
尚未招募
3 期
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal PolyposisNCT07420257CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.212
招募中
2 期
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)NCT07280156Protalix150
尚未招募
3 期
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative ColitisUlcerative Colitis (UC)NCT07650942Ganzhou Hemay Pharmaceutical Co., Ltd360